Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT00395057
Registration number
NCT00395057
Ethics application status
Date submitted
31/10/2006
Date registered
2/11/2006
Date last updated
7/09/2015
Titles & IDs
Public title
A Study Using Intravitreal Injections of a Small Interfering RNA in Patients With Age-Related Macular Degeneration
Query!
Scientific title
Query!
Secondary ID [1]
0
0
211745-001
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Choroid Neovascularization
0
0
Query!
Age-Related Macular Degeneration
0
0
Query!
Condition category
Condition code
Eye
0
0
0
0
Query!
Diseases / disorders of the eye
Query!
Cardiovascular
0
0
0
0
Query!
Other cardiovascular diseases
Query!
Blood
0
0
0
0
Query!
Haematological diseases
Query!
Blood
0
0
0
0
Query!
Other blood disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - AGN 211745
Treatment: Drugs - AGN 211745
Treatment: Drugs - AGN 211745
Treatment: Drugs - Ranibizumab 500µg
Experimental: AGN 211745 Solution 1000 ug - AGN 211745 Solution 1000 ug
Experimental: AGN 211745 Solution 300 ug - AGN 211745 Solution 300 ug
Experimental: AGN 211745 Solution 100 ug - AGN 211745 Solution 100 ug
Active Comparator: Ranibizumab 500 ug - Ranibizumab 500 ug
Treatment: Drugs: AGN 211745
AGN 211745 Solution 1000µg injection at Day 1, Month 1, Month 2
Treatment: Drugs: AGN 211745
AGN 211745 Solution 300µg injections, Day 1, Month 1, Month 2
Treatment: Drugs: AGN 211745
AGN 211745 Solution 100µg injections, Day 1, Month 1, Month 2
Treatment: Drugs: Ranibizumab 500µg
Ranibizumab 500µg injections at Day 1, Month 1, Month 2
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Percentage of Patients With Improvement in Best Corrected Visual Acuity (BCVA) of 15 or More Letters at Month 3
Query!
Assessment method [1]
0
0
Percentage of patients with improvement in BCVA of 15 or more letters at Month 3. BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters). The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved.
Query!
Timepoint [1]
0
0
Month 3
Query!
Secondary outcome [1]
0
0
Lesion Size as Assessed by Fluorescein Angiography (FA) and Photography at Month 3
Query!
Assessment method [1]
0
0
Lesion size as assessed by FA and photography at month 3. FA is a technique for examining the circulation of the retina (and detecting any leakage) using a dye-tracing method. Photographs are taken with a specialized low-power microscope with an attached camera designed to photograph the interior of the eye, including the retina and optic disc.
Query!
Timepoint [1]
0
0
Month 3
Query!
Secondary outcome [2]
0
0
Foveal Thickness as Assessed by Optical Coherence Tomography (OCT) at Month 3
Query!
Assessment method [2]
0
0
Foveal thickness as assessed by OCT at month 3. The fovea is a part of the eye, located in the center of the macula region of the retina. OCT is a laser-based, noninvasive, diagnostic system providing high-resolution, three-dimensional images of the retina. The fovea is responsible for sharp central vision, which is necessary for reading or any activity where visual detail is of primary importance. Normal foveal thickness ranges from 175 to 250 microns. A foveal thickness greater than 250 microns represents worsening vision.
Query!
Timepoint [2]
0
0
Month 3
Query!
Secondary outcome [3]
0
0
Visual Functioning Questionnaire (VFQ) at Month 3
Query!
Assessment method [3]
0
0
Visual Functioning Questionnaire (VFQ) at Month 3. The VFQ includes 25 questions which assess visual impairment on functioning and specific aspects of health-related quality of life. Study terminated; data for this outcome measure were not analyzed.
Query!
Timepoint [3]
0
0
Month 3
Query!
Secondary outcome [4]
0
0
Time to Treatment With Standard of Care at Month 6
Query!
Assessment method [4]
0
0
Time to treatment with standard-of-care at month 6, defined as the number of days before the use of rescue therapy occurred.
Query!
Timepoint [4]
0
0
Month 6
Query!
Eligibility
Key inclusion criteria
- 50 years or older with "wet" AMD as determined by an ophthalmologist
- decrease in visual acuity (20/40 to 20/640) in at least one eye
Query!
Minimum age
50
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Uncontrolled systemic disease
- History of heart attack or stroke within one year of study entry
- Symptomatic coronary artery disease
- Cataracts that interfere with vision
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people assessing the outcomes
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Terminated
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/01/2007
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/02/2009
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
138
Query!
Recruitment in Australia
Recruitment state(s)
NSW
Query!
Recruitment hospital [1]
0
0
- Sydney
Query!
Recruitment postcode(s) [1]
0
0
- Sydney
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Texas
Query!
Country [2]
0
0
Philippines
Query!
State/province [2]
0
0
Makati
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Allergan
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This is a 24-month study to evaluate multiple doses of AGN211745 (previously known as
Sirna-027) in treatment of subfoveal choroidal neovascularization associated with age-related
macular degeneration
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT00395057
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Medical Director
Query!
Address
0
0
Allergan
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT00395057
Download to PDF